Drugs / Investigational TIV-HD2
last change Aug 2019 re-read 2 minutes ago

Investigational TIV-HD2

Vaccine

Developed for
influenza

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT03282240 Comparator Sep → Nov 2017 influenza Sanofi Pasteur, a Sanofi Company Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Investigational TIV-HD2 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03282240
Modality Vaccine “an IIV3-HD containing the alternate B-lineage strain” PMID 31431411 Aug 2019
Route Intramuscular “administered IM into the upper arm area” NCT03282240